Will KETAFREE Become The First FDA-Approved Preservative-Free Ketamine Formulation?

NRx Pharmaceuticals is advancing its lead clinical-stage candidate NRX-100 and is targeting key milestones this year. The announcement is a forward-looking development that is positive for the company’s pipeline but is preliminary and likely to be a modest catalyst for the stock until specific trial or regulatory outcomes are reported.

Analysis

NRx Pharmaceuticals is advancing its lead clinical-stage candidate NRX-100 and is targeting key milestones this year. The announcement is a forward-looking development that is positive for the company’s pipeline but is preliminary and likely to be a modest catalyst for the stock until specific trial or regulatory outcomes are reported.